Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration

Table 1 Delayed-type hypersensitivity responses of naïve and Mycobacterium tuberculosis/incomplete Freund's adjuvant(IFA)-immunized rats

	Ear swelling (mm/100) ± SEM^a
		M. tuberculosis/IFA-immunized	M. tuberculosis/IFA-immunized
Tested peptide	Naïve (n = 3)	day 20 (n = 5)	day 27 (n = 3–4)
OVA_323–339	3.3 ± 1.3	3.4 ± 2.4	ND
MMP-3_444–458	3.3 ± 4.6	30.0 ± 1.3^***,†	14.0 ± 1.7^*,‡
MMP-10_329–343	3 ± 1.5	17.2 ± 3.6^**,†	12.0 ± 2.3^*
MMP-16_539–553	-0.7 ± 0.9	11.4 ± 1.6^**,†	16.3 ± 3.2^*

MMP, matrix metalloproteinase; OVA_323–339, ovalbumin peptide. ^a Mean ± standard error of the mean (SEM) difference in ear swelling between the PBS-treated ear and the peptide-treated ear. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001 difference between PBS-treated ear and the peptide-treated ear (Student's t test); ^†P < 0.05 difference between the M. tuberculosis/IFA-immunized group and the naïve group (Mann–Whitney test); ^‡P < 0.05 difference between the M. tuberculosis/IFA-immunized group at day 20 and at day 27 (Mann–Whitney test). ND, not determined.

ISSN: 1478-6362